摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,5-二甲基-1-丙酰基-哌嗪 | 4204-03-9

中文名称
3,5-二甲基-1-丙酰基-哌嗪
中文别名
——
英文名称
3,5-dimethyl-1-propionyl-piperazine
英文别名
Piperazine, 3,5-dimethyl-1-propionyl-(7CI,8CI);1-(3,5-dimethylpiperazin-1-yl)propan-1-one
3,5-二甲基-1-丙酰基-哌嗪化学式
CAS
4204-03-9
化学式
C9H18N2O
mdl
——
分子量
170.255
InChiKey
XTDNQXLWASUCPP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.4
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.89
  • 拓扑面积:
    32.3
  • 氢给体数:
    1
  • 氢受体数:
    2

文献信息

  • [EN] PYRIDO[3,4-B]INDOLES AND METHODS OF USE<br/>[FR] PYRIDO[3,4-B]INDOLES ET LEURS MÉTHODES D'UTILISATION
    申请人:MEDIVATION TECHNOLOGIES INC
    公开号:WO2011038163A1
    公开(公告)日:2011-03-31
    This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    这份披露涉及可用于调节个体组织中组胺受体的新杂环化合物。描述了吡啶并[3,4-b]吲哚,以及包含这些化合物的药物组合物和使用这些化合物进行各种治疗应用的方法,包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经障碍。
  • [EN] PYRIDO[4,3-B]INDOLES AND METHODS OF USE<br/>[FR] PYRIDO[4,3-B]INDOLES ET LEURS MÉTHODES D'UTILISATION
    申请人:MEDIVATION TECHNOLOGIES INC
    公开号:WO2011038161A1
    公开(公告)日:2011-03-31
    This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    本公开涉及新的杂环化合物,可用于调节个体中的组胺受体。其中描述了吡啶并[4,3-b]吲哚,以及包含这些化合物的药物组合物和使用这些化合物进行各种治疗应用的方法,包括治疗认知障碍、精神病性障碍、神经递质介导的障碍和/或神经元障碍。
  • PYRIDO[3,4-B]INDOLES AND METHODS OF USE
    申请人:HUNG David T.
    公开号:US20090270412A1
    公开(公告)日:2009-10-29
    This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[3,4-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    本公开涉及新的杂环化合物,可用于调节个体中的组胺受体。描述了吡啶并[3,4-b]吲哚类化合物,以及包含该化合物的药物组合物和使用该化合物进行各种治疗应用的方法,包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
  • PYRIDO[4,3-B]INDOLES AND METHODS OF USE
    申请人:Jain Rajendra Parasmal
    公开号:US20110245272A1
    公开(公告)日:2011-10-06
    This disclosure relates to new heterocyclic compounds that may be used to modulate a histamine receptor in an individual. Pyrido[4,3-b]indoles are described, as are pharmaceutical compositions comprising the compounds and methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    本公开涉及新的杂环化合物,可用于调节个体的组胺受体。其中描述了吡啶并[4,3-b]吲哚,以及包含这些化合物的制药组合物和使用这些化合物在各种治疗应用中的方法,包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
  • BRIDGED HETEROCYCLIC COMPOUNDS AND METHODS OF USE
    申请人:MEDIVATION TECHNOLOGIES, INC.
    公开号:US20130190303A1
    公开(公告)日:2013-07-25
    This disclosure relates to new compounds that may be used to modulate a histamine receptor in an individual. Novel compounds are described, including new bridged heterocyclic [4,3-b]indole compounds. Pharmaceutical compositions are also provided. Pharmaceutical compositions comprising the compounds are also provided, as are methods of using the compounds in a variety of therapeutic applications, including the treatment of a cognitive disorder, psychotic disorder, neurotransmitter-mediated disorder and/or a neuronal disorder.
    本公开涉及可用于调节组织胺受体的新化合物。其中描述了新的桥接杂环[4,3-b]吲哚化合物。还提供了制药组合物,包括含有该化合物的制药组合物。还提供了使用该化合物进行各种治疗应用的方法,包括治疗认知障碍、精神障碍、神经递质介导的障碍和/或神经元障碍。
查看更多